Arvinas (ARVN) Revenue Growth (1y) (2018 - 2026)
Arvinas (ARVN) Revenue Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 96.43% |
| 10 | Arvinas | 531.84 Mn | -83.06 Mn | - | -91.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.74% |
| Dec 31, 2025 | -83.95% |
| Sep 30, 2025 | -59.08% |
| Jun 30, 2025 | -70.72% |
| Mar 31, 2025 | 646.25% |
| Dec 31, 2024 | 237.35% |
| Sep 30, 2024 | 195.95% |
| Jun 30, 2024 | 40.37% |
| Mar 31, 2024 | -22.15% |
| Dec 31, 2023 | -214.02% |
| Sep 30, 2023 | 4.22% |
| Jun 30, 2023 | 61.24% |
| Mar 31, 2023 | 22.64% |
| Dec 31, 2022 | 13.86% |
| Sep 30, 2022 | 256.99% |
| Jun 30, 2022 | 514.55% |
| Mar 31, 2022 | 381.82% |
| Dec 31, 2021 | 425.66% |
| Sep 30, 2021 | 22.42% |
| Jun 30, 2021 | -4.31% |